Fig. 1
BRAFV600E CRC cell lines are sensitive to VEM but not to PAN. BRAF-mutant and wildtype cells were exposed to (a, b) vemurafenib (VEM – final concentration 3 μM) or (c, d) panitumumab (PAN – final concentration 8 μg/mL) for 48 h, harvested, and assayed for cell viability (MTS assay) and cell death (trypan blue staining). Results shown are means ± SD of three independent experiments. Statistics (unpaired t-test with equal SD): *p < 0.05, **p < 0.01 vs. CTRL (untreated cells)